Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

• Published in: Molecular cancer Vol. 13; no. 1; p. 114
• Main Authors: Shaw, Victoria E, Lane, Brian, Jenkinson, Claire, Cox, Trevor, Greenhalf, William, Halloran, Christopher M, Tang, Joseph, Sutton, Robert, Neoptolemos, John P, Costello, Eithne
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.05.2014; BioMed Central
• Subjects: Accuracy; Adult; Aged; Analysis; Antigens; Antigens, Tumor-Associated, Carbohydrate - blood; Antigens, Tumor-Associated, Carbohydrate - genetics; Biomarkers; Biomarkers - blood; Biomedical research; Carcinoma, Pancreatic Ductal - blood; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Case-Control Studies; Cholestasis - blood; Cholestasis - diagnosis; Cholestasis - genetics; Cholestasis - pathology; Classification; Confidence intervals; Cytokines; Cytokines - blood; Cytokines - genetics; Diagnosis, Differential; Disease; Female; Gene Expression; Humans; Logistic Models; Logistics; Male; Medical research; Medicine, Experimental; Middle Aged; Pancreas; Pancreas - metabolism; Pancreas - pathology; Pancreatic cancer; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - pathology; Pancreatitis, Chronic - blood; Pancreatitis, Chronic - diagnosis; Pancreatitis, Chronic - genetics; Pancreatitis, Chronic - pathology; Patients; Platelet-Derived Growth Factor - genetics; Platelet-Derived Growth Factor - metabolism
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/1476-4598-13-114

We investigated whether combinations of serum cytokines, used with logistic disease predictor models, could facilitate the detection of pancreatic ductal adenocarcinoma (PDAC). The serum levels of 27 cytokines were measured in 241 subjects, 127 with PDAC, 49 with chronic pancreatitis, 20 with benign biliary obstruction and 45 healthy controls. Samples were split randomly into independent training and test sets. Cytokine biomarker panels were selected by identifying the top performing cytokines in best fit logistic regression models during multiple rounds of resampling from the training dataset. Disease prediction by logistic models, built using the resulting cytokine panels, was evaluated with training and test sets and further examined using resampled performance evaluation. For the discrimination of PDAC patients from patients with benign disease, a panel of IP-10, IL-6, PDGF plus CA19-9 offered improved diagnostic performance over CA19-9 alone in the training (AUC 0.838 vs. 0.678) and independent test set (AUC 0.884 vs. 0.798). For the discrimination of PDAC from CP, a panel of IL-8, CA19-9, IL-6 and IP-10 offered improved diagnostic performance over CA19-9 alone with the training (AUC 0.880 vs. 0.758) and test set (AUC 0.912 vs. 0.848). Finally, for the discrimination of PDAC in the presence of jaundice from benign controls with jaundice, a panel of IP-10, IL-8, IL-1b and PDGF demonstrated improvement over CA19-9 in the training (AUC 0.810 vs. 0.614) and test set (AUC 0.857 vs. 0.659). These findings support the potential role for cytokine panels in the discrimination of PDAC from patients with benign pancreatic diseases and warrant additional study.